Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-1 Registration statement (foreign)
- 3.1 EX-3.1
- 3.2 EX-3.2
- 4.2 EX-4.2
- 4.4 EX-4.4
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 21.1 EX-21.1
- 23.1 EX-23.1
Associated filings
- 21 Jun 21 424B4 Prospectus supplement with pricing info
- 18 Jun 21 EFFECT Notice of effectiveness
- 14 Jun 21 F-1/A Registration statement (foreign) (amended)
-
28 May 21 F-1 Registration statement (foreign)
AMAM similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement on Form F-1 of our report dated March 12, 2021 (May 28, 2021 as to the subsequent events described in Note 14), relating to the financial statements of Ambrx Biopharma Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
San Diego, California
May 28, 2021